{"prompt": "['MC1752', '63', 'Herb/Nutraceutical Interactions: Avoid black cohosh, dong quai in', 'estrogen-dependent tumors.', '15.47 Known potential adverse events: Consult the package insert for the most', 'current and complete information.', 'Common known potential toxicities, > 10%:', 'Central nervous system: Neurotoxicity: Peripheral neuropathy is dose-', 'and duration-dependent', 'Dermatologic: Mild alopecia', 'Gastrointestinal: Nausea and vomiting', 'Hematologic: Anemia, leukopenia (nadir day 18-23, recovery by day 39,', 'dose related), thrombocytopenia (nadir day 18-23, recovery by day 39,', 'dose related)', 'Hepatic: Liver enzymes increased', 'Renal: Nephrotoxicity (acute renal failure and chronic renal', 'insufficiency)', 'Otic: Ototoxicity, manifested as high frequency hearing loss; ototoxicity', 'is especially pronounced in children', 'Less common known potential toxicities, 1% - 10%:', 'Local: Tissue irritation', 'Rare known potential toxicities, <1% (Limited to important or life-', 'threatening):', 'Alopecia, ageusia, anaphylaxis, aortic thrombosis, autonomic neuropathy,', 'bradycardia, cardiac arrhythmia, cardiac failure, cerebrovascular accident,', 'extravasation, hemolytic anemia (acute), hemolytic-uremic syndrome,', 'hiccups, hypercholesterolemia, hyperuricemia, hypocalcemia,', 'hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia,', 'increased serum amylase, leukoencephalopathy, myocardial infarction,', 'neutropenic enterocolitis, optic neuritis, pancreatitis, papilledema,', 'peripheral ischemia (acute), phlebitis, SIADH, tachycardia, thrombotic', 'thrombocytopenic purpura', '15.48', 'Drug procurement: Commercial supplies. Pharmacies or clinics shall obtain', 'supplies from normal commercial supply chain or wholesaler.', '15.49', 'Nursing Guidelines:', '15.491 May react with aluminum IV set, forming a black precipitate and losing', 'its potency.', '15. 492 Assess laboratory values prior to drug administration, especially CBC,', 'platelets, creatinine.', '15. 493 Patient should be hydrated before administration. Stress post infusion', 'hydration maintenance to reduce risk of nephrotoxicity.', '15. 494 Administer aggressive antiemetic therapy pre- and post-treatment.', 'Protocol Version Date: 21JUN2018']['MC1752', '64', '15.495 Monitor for signs of neurotoxicity and ototoxicity. Instruct patient to', 'report any numbness, burning, or tingling in hands and feet to health care team.', 'Also instruct patient to report any changes in hearing or ringing in the ears to', 'health care team.', '15.496 Monitor magnesium and potassium levels, and for signs and symptoms of', 'hypomagnesemia and hypokalemia, supplements may be needed.', '15.497 Instruct patient about alopecia.', '15.498 Use cautiously with loop diuretics as these may increase the risk of', 'ototoxicity.', '15.499aMonitor for signs and symptoms of allergic reactions. Treat according', 'to', \"your institution's protocol.\", '15.499bMonitor renal function tests.', '16.0', 'Statistical Considerations and Methodology', '16.1', 'Overview: This protocol will assess the efficacy and safety of concurrent chemotherapy', 'radiation treatment combined with avelumab in patients with muscle invasive bladder', 'cancer using a two-stage Simon optimum design. A safety run-in with 6 patients', '(described in Section 7.0) will be conducted prior to the expansion portion.', 'A safety analysis will be conducted after 6 patients have been enrolled and have been', 'treated for a minimum of three cycles. Patients will be treated for the first two cycles', 'with avelumab only. Chemoradiation will begin at cycle 3 (Day 29) This will be', 'performed to determine whether or not the proposed combination chemotherapy regimen', '+ radiation therapy with avelumab is a safe regimen. ACCRUAL WILL BE', 'TEMPORARILY HALTED between the safety run-in and expansion portion in order to', 'evaluate the concurrent radiation therapy adverse event. This data will be reviewed by the', 'Study Chair and Study Statistician. The adverse event stopping rule in Section 16.42 will', 'be in effect for patients in the initial safety run-in portion as well as patients in the', 'expansion portion (efficacy portion) of this study. If this regimen at the proposed dosages', 'is deemed safe, these 6 patients will be considered the first 6 patients in this study.', 'Adverse events will continue to be monitored for all subsequent patients per the adverse', 'event stopping rule described in section 16.42.', '16.11 Primary Endpoint: The primary endpoint will be complete response (CR) at 6 months from', 'registration. This study will use the response criteria as described in section 11.0 to evaluate', 'response or progression. The patients enrolled will have nonmeasurable disease on imaging', 'and response will be evaluated with biopsy or cytology at 6 months post-registration. All', 'patients meeting the eligibility criteria who have signed a consent form, have begun treatment,', 'and have not been deemed a major treatment violation during the first cycle of treatment will', 'be evaluable for response.', 'Protocol Version Date: 21JUN2018']\n\n###\n\n", "completion": "END"}